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Specific vulnerability and degeneration of the dopaminergic neurons in the substantia nigra pars compacta of
the midbrain is the pathological hallmark of Parkinson’s disease. A number of transcription factors regulate
the birth and development of this set of neurons and some remain constitutively expressed throughout life.
These maintenance transcription factors are closely associated with essential neurophysiological functions and
are required ultimately for the long-term survival of the midbrain dopaminergic neurons. The current review
describes the role of two such factors, Nurr1 and engrailed, in differentiation, maturation, and in normal
physiological functions including acquisition of neurotransmitter identity. The review will also elucidate the
relationship of these factors with life, vulnerability, degeneration and death of mesencephalic dopaminergic
neurons in the context of Parkinson’s disease.Review
Introduction
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disorder, affecting 1-2% of the popu-
lation over 65 and 3-5% of the people over 85 [1]. The
disease initially manifests with the cardinal motor symp-
toms of rest tremor, bradykinesia, rigidity, and postural
instability. Over time non-motor symptoms such as de-
pression, constipation, pain, genitourinary problems, and
sleep disorders [1,2] become prominent. The main patho-
logical feature of PD is the degeneration of dopaminergic
neurons in the substantia nigra pars compacta (SNpc).
The other nearby mesencephalic dopaminergic (mesDA)
neuronal populations within the ventral tegmental area
(VTA) and retrorubral field (RRF) are less susceptible to
degeneration and remain relatively unaffected during the
course of the disease [3,4].
A wide variety of animal models have been developed to
study the pathological outcomes of cell death in the ven-
tral midbrain and to explore potential therapeutic targets
that can stabilize or remedy the condition [5,6]. In recent
years, characterization of differential gene expression* Correspondence: k.alavian@imperial.ac.uk
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unless otherwise stated.profiles between the two main mesDA neuronal popula-
tions, VTA and SNpc, has been used to probe the question
of relative susceptibility of neurons to environmental and
genetic vulnerability [7]. Another approach to understand
this susceptibility has been the study of the developmental
cues that contribute directly or indirectly to differentiation
of these phenotypes [8].
Based on these studies, we postulate that these neurons
perpetually remain in a developmental state that is vulner-
able to neurodegeneration because the critical period for
naturally-occurring neuron death that occurs for most
populations of neurons never completely closes for these
unique cells in the ventral midbrain. This inherent vulner-
ability of mesDA neurons is a consequence of the unique
expression profile of these cells which is controlled by a
cascade of developmental transcription factors that are not
only required for defining the regional identity of the mid-
brain and specification of mesDA neurons but also for the
long-term survival and maintenance and normal physio-
logical function. Several gain and loss of function studies in
transgenic and mutant animals have demonstrated a strong
connection between developmental factors and essential
neuronal functions such as axon guidance, regulation of
survival and cell death, defining the neurotransmitter
phenotype, neuronal excitability and plasticity [8].
These studies have also established that the insuffi-
ciency in certain key transcription factors can lead toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Alavian et al. Journal of Biomedical Science 2014, 21:27 Page 2 of 7
http://www.jbiomedsci.com/content/21/1/27a neurodegenerative phenotype and subsequently to
PD-like symptoms [9-12].
In this review we will discuss two transcription factors,
engrailed and Nurr1, that are necessary for regulation of
key events in the development of mesencephalic dopa-
minergic neurons as well as their survival and mainten-
ance throughout life. In our discussion, we will highlight
the role of these factors as key transcriptional regulators
of differentiation, maturation and survival of mesDA
neurons, the contribution of each factor to the normal
physiological functions in postnatal mesDA neurons, as
well as their possible connection with the vulnerability
of neurons and etiology of Parkinson’s disease.
Nurr1
Orphan nuclear receptor Nurr1 (nuclear receptor sub-
family 4, group A, member 2; NR4A2) is a member of
the steroid/thyroid hormone nuclear receptor and is
related to a family of factors that modulate transcription
in response to small lipophilic molecules. The transcrip-
tional activity of these factors is regulated through the
interaction of the ligand with the carboxy terminal
ligand-binding domain of specific nuclear receptors [13].
Nurr1 transcription factor is encoded by an immediate
early gene and is predominantly expressed in the brain
[14,15]. Structurally, Nurr1 consists of a DNA binding
domain, a ligand binding domain and two transcription
activation function domains at the N- and C-termini
(AF1 and AF2, respectively) [16,17]. The DNA binding
domain of Nurr1 is highly conserved among the nuclear
receptor family members and is comprised of two zinc
finger modules. This domain is known to activate tran-
scription through binding to an NGFI-B response elem-
ent (NBRE) [18]. Nurr1 lacks a classical binding site for
coactivators and the tight packing of side chains from
hydrophobic residues in the ligand-binding domain pre-
vents the molecule from having a ligand-binding cavity.
The constitutive transcriptional activity of Nurr1, there-
fore, can be attributed to the canonical protein fold resem-
bling the agonist-bound, transcriptionally active, ligand
binding domains in nuclear receptors [19]. Nurr1 also
activates transcription through heterodimerization with
the retionid X receptor (RXR) and in response to the RXR
ligands [20,21]. The AF1 and AF2 domains are also invol-
ved in co-factor recruitment and contribute to the consti-
tutive transcriptional activation of Nurr1 [16,22].
In mice, the expression of Nurr1 can first be detected
on embryonic day 10 (E10) in the ventral midbrain.
Although the expression of the gene is reduced in the
postnatal animals, it continues throughout life and has
been shown to regulate several aspects of postmitotic
development [10,23,24]. The role of Nurr1 in the survival
and differentiation of mesDA neurons was initially discov-
ered through mouse knockout studies, demonstrating lossof immunoreactivity for the rate-limiting enzyme in pro-
duction of dopamine, tyrosine hydroxylase, in the mesDA
neurons from Nurr1 knockout animals [25]. Later on
further studies established that the neuroepithelial cells,
that give rise to mesDA neurons, ventralize normally and
differentiate into neurons. For example, they express
mesDA neuron specific markers such as Pitx3, Ahd2 and
engrailed1/2 and establish nigrostriatal axonal projections,
but lack their dopaminergic phenotype [26-28]. Further
examination of the transcriptional role of Nurr1 demon-
strated that it is an upstream regulator of genes involved
in the synthesis, packaging, transport and reuptake of
dopamine [29,30]. For example, Nurr1 has been shown to
induce the expression of tyrosine hydroxylase (TH) by dir-
ectly transactivating the promoter of TH [31]. Regulation
of the dopamine transporter (DAT) gene is another key
function of Nurr1 in determining the neurotransmitter
phenotype of mesDA neurons. This effect of Nurr1 seems
to be independent of its classic heterodimerization part-
ner, retinoid X receptor. The expression of TH and DAT
is regulated by the high affinity binding of Nurr1 to an
extended half-hormone response element, NGF1-B re-
sponsive element (NBRE), in their 5′-untranslated regions
[32,33]. Finally, other studies have shown that Nurr1 is
involved in conversion of L-DOPA to DA and packaging
of DA into synaptic vesicles by regulating the expres-
sion of aromatic L-amino acid decarboxylase (AADC)
and vesicular monoamine transporter-2 (VMAT2), re-
spectively [30].
In addition to transcriptional regulation of the genes
involved in dopamine production and trafficking, Nurr1
is also a key convert factor in several survival and main-
tenance pathways. Nurr1 regulates the rearranged in
transfection (Ret) gene from the earliest stages in embry-
onic development. Ret tyrosine kinase is the high-affinity
ligand-binding component of the glial cell line derived
neurotrophic factor (GDNF) receptor complex that is
attached to the cell surface via a glycosyl phospha-
tidylinositol anchor [34]. GDNF has been shown to pro-
tect mesDA neurons against the developmental waves of
apoptosis, neurotoxic insults and cell death [35-38]. Upon
GDNF binding, autophosphorylation of the tyrosine do-
mains of Ret triggers activation of several pathways
including PI3K, MAPK which are required for neuronal
survival and neurite outgrowth [39]. Interestingly, one of
the downstream phosphorylation targets of the GDNF
signaling pathway is the cAMP response element binding
(CREB) protein, which is known to directly regulate the
expression of Nurr1 by binding to its promoter [40].
Homozygous Nurr1 knockout pups die shortly after
birth following degeneration of mesDA neurons [25-27].
However, Nurr1 haploinsufficient animals show no signifi-
cant loss of mesDA neuron in number or motor function
until late in life. The aging (>15 months old) Nurr1+/−
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neurons and their locomotor activities, correlated with the
reduced mesolimbic and mesocortical dopamine levels
[9,23]. These animals also display increased vulnerability
and cell death in response to neurotoxic insult [9,41].
The increased neuronal degeneration and death in
these animals is likely to be due to mitochondrial
dysfunction and the opening of the mitochondrial per-
meability transition pore [42]. Transcriptional regulation
of the pro-and anti-apoptotic members of the Bcl-2 mito-
chondrial family of proteins and interaction with theP75
Erk1
En1/2
Metabolic efficiency,
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Bcl2
Bcl-xL
Figure 1 Signaling pathways involved in regulation of cellular surviva
dopaminergic neurons. Transcriptional regulation of several survival/death
protooncogene Ret, as well as modulation of downstream survival mechan
long-term regulation of survival and death of mesDA neurons. Down-regul
of Erk1/2, resulting in survival of mesDA neurons. The effect is similar to the R
pathways regulated by engrailed and Nurr1 converge on mitochondria and a
Bcl2, Bcl-xL and Bax.P53 tumor suppressor protein by Nurr1 are respon-
sible for regulation of mitochondrial survival and
death (Figure 1) [43]. The conditional knockout stud-
ies have further elucidated the role of Nurr1 in the
survival and maintenance of mesDA neurons in the
adult animals, showing that Nurr1-deficiency in ma-
turing neurons results in a rapid loss of striatal dopa-
mine, loss of mesDA specific markers and degeneration
[10]. Taken together, these studies show that Nurr1 regu-
lates both the phenotypic expression and survival of
mesDA neurons in mice.Ret
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l and death by engrailed and Nurr1 in mesencephalic
-regulating genes including the pan-neurotrophin receptor P75 and
isms, such as MAPK (Erk1/2) by engrailed and Nurr1 leads to the
ation of P75 expression by the engrailed genes results in disinhibition
et-mediated activation of Erk1/2 by Nurr1. The survival and degeneration
re mediated by the anti- and pro-apoptotic members of the Bcl-2 family,
Alavian et al. Journal of Biomedical Science 2014, 21:27 Page 4 of 7
http://www.jbiomedsci.com/content/21/1/27Given the neuoprotective role of Nurr1 demon-
strated in animal models and its decreased or dimin-
ished expression levels in PD patients [44,45], a
number of human genetic studies of the Nurr1 gene
were undertaking to identify potential variants that
may increase the risk of developing PD. Although the
results from the studies within the past decade have
failed to establish the mutations in Nurr1 as a cause
or direct risk factor for PD, higher incidence of several
mutations within the coding and non-coding regions of
Nurr1 have been observed in familial and sporadic cases
of the disease [46-49].
A number of these mutations have been associated
with a marked decrease in the level of Nurr1 expression
and subsequent reduction in the expression of TH [46].
The evidence from these studies accompanied by the
results of the postmortem expression analysis in the PD
patient brains suggest dysregulation of Nurr1 as a contrib-
uting factor to the onset and progression of neurodegener-
ation during the course of PD.
The engrailed transcription factors
The engrailed genes belong to the family of homeobox
transcription factors, containing a highly conserved DNA
binding, helix-turn-helix, homeodomain protein fold [50].
The morphological significance of the engrailed was first
described in drosophila, where the autosomal mutant
displays a long cleft of the thorax and irregular venation
of the wings [51]. In addition to its early role in body
segmentation, engrailed homologs in various annelid,
mollusks, chordate and arthropod species has revealed a
separate major function in neurogenesis [52-54]. Interest-
ingly, homologs of engrailed are conserved among differ-
ent phyla, to the degree that replacement of the mouse
engrailed-1 gene by its paralog En2 or by the drosophila
engrailed homolog will preserve its function in develop-
ment and survival [55,56].
The engrailed genes have two distinct functions during
early and late development. The two paralogs of en-
grailed, En1 and En2, start their expression around E8 in
mice in a broad region at the midbrain/hindbrain border,
known as the isthmic organizer [57]. During this period,
engrailed is involved in the induction of mesDA neurons
by maintaining expression of Fgf8 in this region [58-60].
En1/2 directly regulate the expression of Fgf8 through
interaction with a DNA-binding intronic fragment on
Fgf8 [61]. In En1/2 deficient embryos the domain of
expression of Fgf8 in the isthmus is reduced and leads
an incomplete induction of mesDA neurons in the mid-
brain. The specific expression of the engrailed genes in
mesDA neurons starts after the neurons are induced and
become postmitotic, between E11.5 and E14 in mice
[62]. After this point, expression of both engrailed genes
is required for continued survival of these neurons.Mouse knockout studies have shown that there is a
direct correlation between the dose of expression of
engrailed and its survival effect in mesDA neurons. Mice
lacking all four alleles of the two transcription factors
(En1−/−;En2−/−) show the most severe phenotype. In
these mice, the induction of dopaminergic neurons in
the ventral midbrain is affected, the differentiated post-
mitotic mesDA neurons display significant developmen-
tal defects including a lack of axonal outgrowth and
eventually die between E12 and E14, matching the time-
frame of the expression of engrailed genes in wildtype
mesDA neurons [62,63]. The postmitotic survival effect
of En1 is more prominent than that of En2, since the
mice lacking En2 show less severe phenotypes than the
En1−/− animals. All En1−/− animals (regardless of the
expression of En2) exhibit an abnormal distribution of
dopaminergic neurons in ventral midbrain and die at
birth. En1+/+;En2−/− mice, however, are viable and
fertile and show no obvious deficiencies with regard to
their dopaminergic neurons [62,64]. The most interest-
ing phenotype among the engrailed-deficient animals is
that of the mice heterozygous for En1 and homozygous
null for En2 (En1+/−;En2−/−) where the development of
mesDA neurons seems to be normal until just after birth
when 70% of the neurons are lost within the first three 3
postnatal months. This specific nigral dopaminergic cell
loss is accompanied by diminished dopamine levels and
release within the dorsal striatum, leading to a marked
decrease in locomotion, an increase in freezing episodes
and weight loss.
Engrailed regulates development, survival and mainten-
ance of mesDA neurons through the cooperative action of
multiple molecular pathways. Cell death in absence of
engrailed is mediated by at least two molecular pathways,
involving the pan-neurotrophin receptor, P75NTR and
the mitochondria. The increase in expression of the
neurotrophin receptor P75 is a common phenomenon ob-
served in neuronal injury and naturally-occurring neuron
death [65]. Similarly, engrailed deficiency causes an in-
crease in the expression of P75 resulting in downregula-
tion of the mitogen activated protein kinase (MAPK)
survival pathways and deactivation of the extracellular
regulated kinases Erk1/2 [66]. A second survival mech-
anism regulated by the expression of the engrailed
genes affects the mitochondria. Similar to the Nurr1
haploinsufficient cells, the mesDA neurons heterozy-
gous for En1 (either in presence or absence of En2) are
more prone to mitochondrial insult and cell death
induced by inhibition of the complex-I of the electron
transport chain than their wildtype counterparts [66].
The dose-dependent survival role of the engrailed genes
against mitochondrial instability is suggestive of another
link between engrailed and the etiology of PD, since mito-
chondrial dysfunction has been implicated as one of the
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ogy of Parkinson’s disease [66-69].
These studies on the engrailed knockout animals
spurred a search for mutant genes in humans with Parkin-
son’s disease. These studies have established a significant
association between sporadic PD and single nucleotide
polymorphisms (SNPs) in an intronic region of En1, on
the 3′ downstream region of En1 and the promoter region
of En2 [70-72].
Conclusions
Degeneration of dopaminergic neurons in the substantia
nigra pars compacta is pathological hallmark of PD that
is responsible for most of the motor symptoms of the
disease. The inherent vulnerability of this neuronal
population, as a root cause for degeneration, is attrib-
uted to the distinct gene expression profile of mesDA
neurons in this region, which sets them apart from the
neighboring neurons in the ventral tegmental area
[73-75]. There is ample evidence suggesting that this
basic physiological feature (i.e. vulnerability to degener-
ation) of the neurons and the underlying specific gene
expression profile are defined very early on during the
time that the cells assume their positional identity, become
postmitotic and express their dopaminergic phenotype,
even before the onset of axonal outgrowth. Some of the
most compelling and direct evidence in support of this
argument comes from the studies on the mice lacking the
homeodomain transcription factor Pitx3, where the devel-
opment of the neurons is halted, resulting in cell death
only in the substantia nigra around E12 [76]. The engrailed
transcription factors and Nurr1 begin their expression in
mesDA neurons during the same time and, to a large
extent, define the molecular identity of these neurons
throughout life.
Given the gene-dose-dependent loss of mesDA neurons
in the engrailed deficient mice and the severe mesDA-
specific defects in the Nurr1 knockout animals, it can be
concluded that the main role of these two factors beyond
this critical period (E12-E14 in mice) is to protect the ni-
gral dopaminergic neurons by maintaining the survival
cues that are most active during the developmental and
early stages of the life of mesDA neurons. The insights
into the transcriptional regulation of survival by these
factors, therefore, may provide an insight into the core
issue of the specific vulnerability of nigral dopaminergic
neurons. In recent years, a number of studies have re-
vealed some of the downstream transcriptional targets
and survival mechanisms that converge at the level of
mitochondria and downstream of growth factors [66,67].
The expression of engrailed genes indirectly determines
the level of phosphorylation of two mitogen activated
protein kinase (MAPK) family members, Erk1/2, which act
as mediators of survival, proliferation and differentiation inresponse to growth factors [66]. Erk1/2 as well as the other
member of the MAPK family, Erk5, are known to contrib-
ute to the expression of TH, differentiation as well as sur-
vival of mesDA neurons by elevating the transcriptional
activity of Nurr1 (Figure 1) [77,78]. Erk1/2 can also cause
phosphorylation, nuclear localization and activation of
Nurr1, which in turn affects the expression levels of
tyrosine hydroxylase. This mechanism is related to the
expression of the autosomal recessive early onset PD gene
DJ-1 (Figure 1) [79].
En1/2 and Nurr1 expression also prevents mitochondrial
impairment, a well described pathogenic phenomenon in
Parkinson’s disease, by inhibiting neurotoxic insult and the
mitochondrial pathway of apoptosis, through regula-
tion of the pro- and anti-apoptotic member of Bcl-2
family (Figure 1) [43,66,80]. This function of the two
transcription factors is likely to prevent the cells from
undergoing mitochondrial permeability transition, which
occurs in response to death stimuli. While the opening of
the mitochondrial permeability transition pore is generally
considered an acute pathological phenomenon, under
certain conditions such as metabolic stress, it is plausible
that subtle changes in the mitochondrial membrane po-
tential or uncoupling of the mitochondrial inner mem-
brane would result in chronic neurodegeneration. This
mechanism is more likely to be the target for the
long-term protective effects of engrailed and Nurr1.
The molecular nature of this protective function remains
to be determined.
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